Securities Law

Willow Lane's merger with AI cloud provider Boost Run is on hold pending SEC approval, highlighting regulatory hurdles in the high-stakes GPU compute race.

American Ventures publicizes support from 85+ investors, a move to counter a recent fraud lawsuit and an ongoing SEC investigation into its practices.

An ETF offers retail investors a ticket to SpaceX's massive IPO, but a bitter public dispute with critics raises questions about transparency and risk.

OTC-listed APPlife Digital Solutions is launching weekly investor calls, a bold move to build trust. But can it overcome its financial hurdles?

With the FDA mandating a move from animal testing, BioIVT is positioning itself at the center of the NAMs revolution with key industry events and research.

As AI and tech lawsuits surge, a specialized list of legal experts emerges to handle complex disputes beyond the courtroom. Here's why it matters.

As spring car shopping begins, buyers face a surge in sophisticated fraud. Learn how to spot odometer rollbacks, VIN cloning, and other hidden traps.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

The parent of Meineke and Maaco admits to 'material errors' in its financials, triggering a massive stock sell-off and a wave of investor lawsuits.

Eleven Ohio families won a landmark $2.3M arbitration award after their advisor breached its duty. The case sends a stark warning to the entire industry.

Facing volatile markets, AVAX One pushes for regulatory clarity at the DC Blockchain Summit, aiming to legitimize Avalanche for institutional investors.

A lawsuit alleges Stephen K. Bannon and associates misled investors in a politically-themed crypto scheme, pocketing fees while the tokens collapsed.

With the hire of Robert Spake as General Counsel, Forum Markets signals a major push for regulatory discipline in the high-stakes race to tokenize real-world assets.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

The company unveils a five-pillar ecosystem for its $SNACK token, targeting everything from Premier League payments to real estate and iGaming.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

Mark Hunt, the architect of SIM's rise to an $86B powerhouse, has stepped down, leaving questions about the future of the firm he built from the ground up.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

The Chinese education firm is back in the NYSE's good graces, but a 12-month review period means the real test of stability has just begun.